Aristides Capital’s Epizyme, Inc EPZM Stock Holding History

Aristides Capital’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-16,552	Closed	-$266K	–	130
2020 Q2	$266K	Buy	+16,552	New	+$289K	0.2%	71

Other funds holding EPZM

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Aristides Capital's EPZM Position: Q3 2020 in Review

Aristides Capital sold out of Epizyme, Inc (EPZM) in Q3 2020, closing a stake of 16,552 shares — an estimated $266K sold.

Aristides Capital first reported a position in EPZM in Q2 2020 and held it in 1 quarter. The position peaked at $266K in Q2 2020. 151 funds tracked by Wall St. Rank hold EPZM as of Q3 2020.

Aristides Capital reported no remaining Epizyme, Inc position as of Q3 2020 after selling out during the quarter.
Aristides Capital sold 16,552 Epizyme, Inc shares in Q3 2020, an estimated $266K.
Aristides Capital first reported a position in Epizyme, Inc in Q2 2020 and held it in 1 quarter.
Aristides Capital's Epizyme, Inc position peaked at $266K in Q2 2020.
151 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2020.

Based on Aristides Capital's 13F filing for Q3 2020, filed 12 Nov 2020.